Company Description
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia.
The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s.
Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers.
The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Ram Mukunda |
Contact Details
Address: 10224 Falls Road Potomac, Maryland 20854 United States | |
| Phone | 301 983 0998 |
| Website | igcpharma.com |
Stock Details
| Ticker Symbol | IGC |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 1326205 |
| CUSIP Number | 45408X308 |
| ISIN Number | US45408X3089 |
| Employer ID | 20-2760393 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ram Mukunda | Founder, President, Chief Executive Officer and Director |
| Benysh Qureshi Esq., M.B.A. | Director of Operations |
| Rohit Goel CPA, M.B.A. | Director of Accounting and Senior Director |
| Susana Salgar | Sales Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 30, 2026 | 8-K | Current Report |
| Mar 18, 2026 | 10-KT | Filing |
| Mar 12, 2026 | 8-K | Current Report |
| Jan 6, 2026 | 8-K | Current Report |
| Jan 6, 2026 | 424B5 | Filing |
| Jan 2, 2026 | 8-K | Current Report |
| Dec 15, 2025 | 8-K | Current Report |
| Dec 5, 2025 | EFFECT | Notice of Effectiveness |
| Dec 3, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 17, 2025 | S-3 | Registration statement under Securities Act of 1933 |